Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $19.00

Travere Therapeutics (NASDAQ:TVTX) had its target price upped by HC Wainwright from $17.00 to $19.00 in a research note issued to investors on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Travere Therapeutics’ FY2025 earnings at ($1.80) EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $1.98 EPS and FY2028 earnings at $4.29 EPS.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company increased their price objective on Travere Therapeutics from $8.00 to $9.00 and gave the company an equal weight rating in a research report on Friday, February 16th. Piper Sandler raised their target price on Travere Therapeutics from $10.00 to $11.00 and gave the stock a neutral rating in a research report on Thursday, January 18th. Guggenheim reissued a neutral rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Finally, Wedbush reissued an outperform rating and issued a $13.00 target price on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus price target of $18.00.

Travere Therapeutics Trading Down 2.4 %

Travere Therapeutics stock opened at $5.26 on Wednesday. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.47 and a quick ratio of 3.41. Travere Therapeutics has a one year low of $5.12 and a one year high of $22.75. The stock has a market capitalization of $400.33 million, a PE ratio of -3.27 and a beta of 0.58. The business’s fifty day moving average is $7.28 and its 200 day moving average is $7.65.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.11. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. The company had revenue of $45.06 million for the quarter, compared to analysts’ expectations of $41.25 million. On average, sell-side analysts predict that Travere Therapeutics will post -3.1 EPS for the current year.

Insider Transactions at Travere Therapeutics

In other news, SVP William E. Rote sold 4,764 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.71, for a total value of $41,494.44. Following the transaction, the senior vice president now owns 80,720 shares of the company’s stock, valued at $703,071.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP William E. Rote sold 4,764 shares of Travere Therapeutics stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.71, for a total transaction of $41,494.44. Following the sale, the senior vice president now owns 80,720 shares of the company’s stock, valued at approximately $703,071.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric M. Dube sold 19,122 shares of Travere Therapeutics stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.70, for a total value of $166,361.40. Following the sale, the chief executive officer now directly owns 350,600 shares in the company, valued at approximately $3,050,220. The disclosure for this sale can be found here. Insiders have sold 34,773 shares of company stock valued at $300,625 over the last quarter. 3.75% of the stock is currently owned by company insiders.

Institutional Trading of Travere Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC raised its stake in Travere Therapeutics by 1,656.4% during the 4th quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after purchasing an additional 2,849 shares during the period. Nisa Investment Advisors LLC grew its holdings in Travere Therapeutics by 968.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock valued at $51,000 after buying an additional 5,121 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Travere Therapeutics by 353.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock valued at $78,000 after buying an additional 6,773 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Travere Therapeutics during the 4th quarter valued at approximately $137,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Travere Therapeutics by 32.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,511 shares of the company’s stock valued at $148,000 after buying an additional 4,007 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.